Fastex Exchange has announced a new listing for its users. The exchange has integrated the VeChainThor blockchain and its native token VET. The new spot trading pair VET/USDT is now open for trading on the Fastex Exchange.

 

Deposit for VET:

Opens on 22/02/2025, at 16:00 (UTC+4)

 

Trading for VET/USDT:

Begins on 22/02/2025, at 16:00 (UTC+4)

 

Withdrawals for VET:

Available from 22/02/2025, at 16:00 (UTC+4)

 

About VeChain Blockchain

VeChain is an enterprise-focused blockchain designed to optimize supply chains and business operations. Built on the VeChainThor blockchain, it uses a dual-token system where VET facilitates transactions and governance while VTHO covers fees, ensuring cost stability. Operating on a Proof of Authority (PoA) consensus, VeChain delivers fast, low-energy transactions. Companies like Walmart China and BMW leverage its technology for transparent and efficient supply chain management.

 

Join our community:

X

Telegram

Discord

 

Important Notice:

In accordance with the applicable provisions of the MiCA regulation that are now in effect, USDT will no longer be available to EEA residents.

Disclaimer: 

Not investment advice. All trading carries risk. Only risk capital you can afford to lose.

 

Risk warning: 

The prices of digital assets are inherently exposed to substantial market risks and unpredictable fluctuations. The worth of your investment can decrease or increase, and it's possible that you won't recover the sum invested. You are the only one accountable for your investment choices, and Fastex disclaims any responsibility for potential losses you might experience. The performance of assets in the past doesn't guarantee similar outcomes in the future. It's advisable to only invest in financial instruments that you comprehend and whose risks you are aware of. Before committing to any investment, reflect on your investment background, financial condition, investment goals, and your capacity to absorb risks, and consider seeking advice from an independent financial consultant. This information should not be interpreted as financial guidance. For additional details, please refer to our Terms of Use and General Risk Disclaimer.